Mirzaian Elham, Doustmohammadi Tahereh, Panahi Mahshid, Sarmadi Soheila, Ameli Fereshteh, Nili Fatemeh
Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehan, Iran.
Iran J Pathol. 2024 Spring;19(2):218-224. doi: 10.30699/IJP.2024.2016228.3217. Epub 2024 Jan 29.
BACKGROUND & OBJECTIVE: GATA3 immunohistochemistry has been described as a highly sensitive marker in determining carcinomas of breast and urothelial origin. In the gynecologic system, it can be used as a marker to diagnose mesonephric or mesonephric-like carcinomas and trophoblastic tumors. The present study was performed to determine the diagnostic value of GATA3 in gynecological adenocarcinomas.
A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.
A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.
GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.
GATA3免疫组化已被描述为确定乳腺和尿路上皮来源癌的高敏标志物。在妇科系统中，它可作为诊断中肾或中肾样癌及滋养层肿瘤的标志物。本研究旨在确定GATA3在妇科腺癌中的诊断价值。
对187例来自不同类型子宫内膜癌、子宫颈管内膜癌和卵巢癌的样本进行分析，以确定肿瘤细胞中GATA3表达的强度和百分比。研究GATA3表达与临床病理参数之间的关系。
共调查了187例患者，包括101例卵巢腺癌、77例子宫内膜腺癌和9例子宫颈管内膜腺癌。在5.1%（4/77）的子宫内膜腺癌、12.9%（13/101）的卵巢腺癌和11.1%（1/9）的子宫颈管内膜腺癌中观察到该标志物呈弱和局灶性表达。所有亚型的平均H评分均低于10.6（2 - 35）。肿瘤细胞中GATA3表达与临床分期、肿瘤复发或转移之间无统计学显著相关性。
GATA3在大多数常见妇科腺癌中表达罕见、微弱或呈局灶性。
